There is accumulating evidence that leukemias and other hematologic diseases are
angiogenesis-dependent. Therefore, angiogenesis inhibitors may be useful adjuncts to
conventional therapies in the treatment of these diseases. When all conventional therapy
has failed, an angiogenesis inhibitor may be successfully used alone, as has been
demonstrated in the treatment of multiple myeloma by thalidomide. The experimental and
clinical evidence that the efficacy of thalidomide against multiple myeloma is mediated in …